<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674440</url>
  </required_header>
  <id_info>
    <org_study_id>04-003683</org_study_id>
    <secondary_id>FD-R-003457-01</secondary_id>
    <nct_id>NCT00674440</nct_id>
  </id_info>
  <brief_title>Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism</brief_title>
  <official_title>Localization of Focal Forms of Hyperinsulinism of Infancy With 18F-labeled L-fluoro-DOPA PET Scan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with congenital hyperinsulinism (CHI) have low blood sugar, and some of these
      children may require surgery. In this study, researchers affiliated with the University of
      Pennsylvania will test how well a radioactive drug (called F-DOPA) can detect a form of
      hyperinsulinism that may be cured by surgery. Eligible participants in this study will have
      positron emission tomography (PET) scans with F-DOPA prior to surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For children with congenital hyperinsulinism (CHI), low blood sugar is caused by cells in the
      pancreas that release too much insulin. Some children with CHI have these cells throughout
      their pancreas; others have them located in specific areas of the pancreas. Children who have
      them located in specific areas of the pancreas may be cured with surgery. F-DOPA is a
      radioactive drug that may go to these very cells. F-DOPA can also be used for positron
      emission tomography (or PET), an imaging technique used in nuclear medicine departments. In
      this study, researchers will test the possibility of using PET with F-DOPA in the diagnosis
      of children with hyperinsulinism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ability of FDOPA PET to identify forms of hyperinsulinism that may be cured by surgery: focal forms.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess safety of F-DOPA PET.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <condition>Hyperinsulinism</condition>
  <condition>Persistent Hyperinsulinemic Hypoglycemia of Infancy</condition>
  <condition>CHI</condition>
  <condition>PHHI</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and will be scheduled for surgery. Eligible children in this arm will PET imaging with F-DOPA prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children diagnosed with hyperinsulinism who have had partial pancreas removal but still display signs of hyperinsulinism. Eligible children in this arm may have PET imaging with F-DOPA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children diagnosed with hyperinsulinism who are successfully managed with diazoxide, octreotide, other medications,and/or tube feedings. Eligible children in this arm will PET imaging with F-DOPA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-DOPA</intervention_name>
    <description>0.08-0.16 mCi/kg once</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>18F-labeled L-fluorodeoxyphenylalanine</other_name>
    <other_name>18F-DOPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET scan</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any age, but primarily infants 0-6 months.

          -  Children with confirmed diagnosis of congenital hyperinsulinism.

        Exclusion Criteria:

          -  Cases in which surgery will not be considered by parents or guardians.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa J States, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hyperinsulinism.chop.edu.</url>
    <description>The Congenital Hyperinsulinism Center at The Children's Hospital of Philadelphia</description>
  </link>
  <link>
    <url>http://www.congenitalhi.org/</url>
    <description>International non-profit organization created by parents/families based in the United States</description>
  </link>
  <reference>
    <citation>Hardy OT, Litman RS. Congenital hyperinsulinism - a review of the disorder and a discussion of the anesthesia management. Paediatr Anaesth. 2007 Jul;17(7):616-21. Review.</citation>
    <PMID>17564642</PMID>
  </reference>
  <reference>
    <citation>Otonkoski T, Näntö-Salonen K, Seppänen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekström K, Guiot Y, Rahier J, Laakso M, Rintala R, Nuutila P, Minn H. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes. 2006 Jan;55(1):13-8.</citation>
    <PMID>16380471</PMID>
  </reference>
  <reference>
    <citation>Ribeiro MJ, Boddaert N, Delzescaux T, Valayannopoulos V, Bellanné-Chantelot C, Jaubert F, Verkarre V, Nihoul-Fékété C, Brunelle F, De Lonlay P. Functional imaging of the pancreas: the role of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy. Endocr Dev. 2007;12:55-66.</citation>
    <PMID>17923769</PMID>
  </reference>
  <reference>
    <citation>Subramaniam RM, Karantanis D, Peller PJ. [18F]Fluoro-L-dopa PET/CT in congenital hyperinsulinism. J Comput Assist Tomogr. 2007 Sep-Oct;31(5):770-2.</citation>
    <PMID>17895790</PMID>
  </reference>
  <reference>
    <citation>Ribeiro MJ, Boddaert N, Bellanné-Chantelot C, Bourgeois S, Valayannopoulos V, Delzescaux T, Jaubert F, Nihoul-Fékété C, Brunelle F, De Lonlay P. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2120-8. Epub 2007 Jul 28.</citation>
    <PMID>17661030</PMID>
  </reference>
  <reference>
    <citation>de Lonlay P, Simon-Carre A, Ribeiro MJ, Boddaert N, Giurgea I, Laborde K, Bellanné-Chantelot C, Verkarre V, Polak M, Rahier J, Syrota A, Seidenwurm D, Nihoul-Fékété C, Robert JJ, Brunelle F, Jaubert F. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J Clin Endocrinol Metab. 2006 Mar;91(3):933-40. Epub 2006 Jan 10.</citation>
    <PMID>16403819</PMID>
  </reference>
  <results_reference>
    <citation>Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R, Zhuang H, MacMullen C, Becker S, Adzick NS, Divgi C, Alavi A, Stanley CA. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2007 Dec;92(12):4706-11. Epub 2007 Sep 25.</citation>
    <PMID>17895314</PMID>
  </results_reference>
  <results_reference>
    <citation>Hardy OT, Hernandez-Pampaloni M, Saffer JR, Suchi M, Ruchelli E, Zhuang H, Ganguly A, Freifelder R, Adzick NS, Alavi A, Stanley CA. Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr. 2007 Feb;150(2):140-5.</citation>
    <PMID>17236890</PMID>
  </results_reference>
  <results_reference>
    <citation>Hussain K, Seppänen M, Näntö-Salonen K, Adzick NS, Stanley CA, Thornton P, Minn H. The diagnosis of ectopic focal hyperinsulinism of infancy with [18F]-dopa positron emission tomography. J Clin Endocrinol Metab. 2006 Aug;91(8):2839-42. Epub 2006 May 9.</citation>
    <PMID>16684819</PMID>
  </results_reference>
  <results_reference>
    <citation>Blomberg BA, Moghbel MC, Saboury B, Stanley CA, Alavi A. The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis. Mol Imaging Biol. 2013 Feb;15(1):97-105. doi: 10.1007/s11307-012-0572-0. Review.</citation>
    <PMID>22752652</PMID>
  </results_reference>
  <results_reference>
    <citation>Peranteau WH, Palladino AA, Bhatti TR, Becker SA, States LJ, Stanley CA, Adzick NS. The surgical management of insulinomas in children. J Pediatr Surg. 2013 Dec;48(12):2517-24. doi: 10.1016/j.jpedsurg.2013.04.022.</citation>
    <PMID>24314196</PMID>
  </results_reference>
  <results_reference>
    <citation>Laje P, Palladino AA, Bhatti TR, States LJ, Stanley CA, Adzick NS. Pancreatic surgery in infants with Beckwith-Wiedemann syndrome and hyperinsulinism. J Pediatr Surg. 2013 Dec;48(12):2511-6. doi: 10.1016/j.jpedsurg.2013.05.016.</citation>
    <PMID>24314195</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <disposition_first_submitted>January 25, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 25, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2013</disposition_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Lisa States</investigator_full_name>
    <investigator_title>Attending Physician/Radiologist</investigator_title>
  </responsible_party>
  <keyword>Congenital Hyperinsulinism</keyword>
  <keyword>Hyperinsulinism</keyword>
  <keyword>Persistent Hyperinsulinemic Hypoglycemia of Infancy</keyword>
  <keyword>CHI</keyword>
  <keyword>PHHI</keyword>
  <keyword>F-DOPA</keyword>
  <keyword>L-fluoro-dihydroxyphenylalanine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroxyphenylalanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

